Bass, Berry & Sims recently participated as a platinum sponsor of the 2nd Annual Kayo Healthcare Private Equity Summit, held June 22–23, in Washington, D.C. The Summit brought together a curated group of investors, operators, and advisors for two days of networking and dialogue on healthcare private equity trends, regulatory developments, and emerging investment opportunities shaping the sector.
As part of the program, Bass, Berry & Sims attorneys led several panels and discussions, convening leading voices across private equity, corporate venture, and healthcare operations. These sessions explored how organizations are navigating operational complexity, deploying artificial intelligence (AI) at scale, aligning enterprise-driven innovation, and evaluating high-growth consumer health platforms. The discussions highlighted a clear shift toward execution discipline, scalable operating models, and durable value creation as the defining drivers of success in healthcare investing.
Private Equity’s Impact on Healthcare
“Strategy is consistent—the difference in outcomes comes down to how well organizations execute at the market level.”
Panelists provided a detailed view into how private equity is fundamentally reshaping healthcare operations, particularly across physician services, women’s health, home-based care, and multi-site provider platforms. The discussion emphasized that private equity has evolved beyond a capital provider into a driver of operational infrastructure and scalability, often serving as the mechanism that allows providers to remain competitive in the face of rising regulatory burden, reimbursement pressure, and technology demands.
Speakers described the challenges inherent in scaling healthcare businesses, particularly in fragmented markets where integration must account for local variations in workforce dynamics, reimbursement structures, and patient populations. Standardized 100-day plans or centralized rollout strategies often require significant adaptation, reinforcing that healthcare growth cannot be approached with a purely industrial or uniform playbook. Panelists also highlighted that the most reliable indicators of success are operational, provider retention, caregiver engagement, patient access metrics, and cash flow stability, rather than purely financial outputs. Across segments such as home care and specialty physician platforms, workforce engagement was repeatedly identified as a critical lever, with cultural alignment directly influencing both quality outcomes and margin performance.
Moderator: Lara Flatau (Bass, Berry & Sims)
Panelists: LeAnne Stewart (Healthcare Outcomes Performance), CJ Rambler (HonorHealth), Harriet Booker (Unified Women’s Healthcare), Jennifer Meyers (Marwood Group)
Impact of AI on Healthcare Investing
“AI is no longer the experiment—it’s the operating layer. The challenge now is adoption and scale.”
This panel offered a practical perspective on how private equity firms are operationalizing AI across healthcare portfolios, focusing on where real value is emerging versus where early enthusiasm has not translated to impact. Panelists emphasized that AI’s most meaningful contributions today are concentrated in high-volume, structured workflows, including revenue cycle management, coding, scheduling, and administrative processes, where improvements can be directly measured through productivity gains, cost reduction, and increased throughput.
A key insight was that the barrier to value creation is not technological capability but organizational adoption, with many firms still working to close the gap between pilot programs and scalable deployment. Successful implementations were described as those that are embedded within business functions, owned by operators (not solely IT), and tied to clearly defined key performance indicators (KPIs) that are already tracked within the organization. The conversation also explored the importance of data quality, governance, and risk frameworks, particularly given the sensitivity of healthcare data and the regulatory environment, as well as balancing outsourcing and in-house IP creation using AI. While panelists acknowledged the long-term potential of AI in clinical decision-making, consensus was that near-term value will continue to center on augmenting human workflows rather than replacing them, especially in areas requiring judgment and compliance oversight.
Moderators: Tatjana Paterno (Bass, Berry & Sims), Sheila Shah (L.E.K. Consulting)
Panelists: Jin On (Frazier Healthcare Partners), Samantha Gordon Webb (Revelstoke Capital Partners), Christine Livingston (Arsenal Capital Partners)
Keynote Conversation: Corporate Venture & Enterprise-Driven Innovation
“The goal isn’t just to invest—it’s to create pathways for these companies to scale within the enterprise.”
This fireside chat discussion explored the role of corporate venture capital as a bridge between emerging innovation and large-scale enterprise adoption. The conversation highlighted how organizations like CVS Ventures operate with a dual mandate: supporting current enterprise priorities while investing in solutions that anticipate future needs, often identifying technologies or platforms that are ahead of internal readiness.
A central theme was that AI acts as a force multiplier across nearly all innovation categories, blurring traditional sector distinctions and expanding the range of investable opportunities. The discussion emphasized that successful corporate venture investing is highly thesis-driven, grounded in identifying unmet needs within the enterprise and sourcing solutions that can meaningfully address them. At the same time, the ability to translate investment into impact depends on deep integration with business units, facilitating internal introductions, validating use cases, and helping portfolio companies navigate complex organizational structures. Panelists noted that one of the most common barriers to scaling innovation is reliance on a single internal sponsor; instead, success requires building broad-based support across clinical, operational, and executive stakeholders. Over time, trust between venture teams and operating divisions becomes a significant competitive advantage in accelerating adoption and driving value creation.
Moderator: Rachel Byrd (Bass, Berry & Sims)
Speaker: Andrea Messina (CVS Health Ventures)
Health, Wellness & the New Front Door to Care
“Marketing buys attention; evidence and experience buy staying power.”
This panel explored the rapid expansion of consumer‑driven, largely cash‑pay healthcare, with a focus on med spas, GLP‑1‑based weight management programs, supplements, and broader wellness and longevity offerings. Panelists described the space as high‑growth and increasingly crowded, but also more rigorously scrutinized as investors move beyond “growth at all costs” and concentrate on durable unit economics and true business quality.
The conversation highlighted a clear move away from single‑service, fad‑driven concepts toward integrated, multi‑channel platforms that track consumers across their full health and aesthetic journey. These models blend weight management, aesthetics, preventive care, and ongoing wellness programs into a unified experience rather than a set of standalone offerings. When done well, this evolution unlocks greater lifetime value and deeper relationships, as patients return for multiple needs over time rather than isolated episodes of care. But it also raises the bar on execution, demanding robust clinical governance, a consistently high‑quality experience across locations and digital touchpoints, and the ability to attract, train, and retain specialized talent capable of delivering both medical rigor and premium service. Importantly, behind the glossy growth stories, the risk checks told the real tale. Regulatory compliance, product sourcing, scientific and clinical validation, and data integrity emerged as critical pressure points. Weakness in any one area can rapidly compress valuation. Digital marketing and influencer‑led growth remain powerful acquisition engines, but the panel emphasized that “TikTok‑native” brands without evidence or defensible compliance are increasingly failing investor scrutiny.
Ultimately, the group agreed that the long‑term winners in consumer health will be those that can:
- Prove measurable clinical outcomes rather than rely solely on testimonials or trends.
- Deliver credible brand promises and avoid over‑claiming in marketing and influencer campaigns.
- Earn and maintain patient trust, particularly in women’s health and other historically underserved areas.
- Drive repeat utilization instead of one‑time, promotion‑driven visits.
- Embed services into ongoing routines and lifestyle habits, creating true stickiness.
- Generate retention and predictable revenue through subscriptions, memberships, and longitudinal care.
- Avoid over‑reliance on a single product or trend (such as GLP‑1s) or a single acquisition channel.
- Flex across evolving consumer trends while maintaining evidence‑based results and strong compliance.
- Proactively manage regulatory risk, positioning themselves as attractive platforms for sophisticated capital and strategic acquirers.
Models built narrowly around one product, one fad, or one channel were noted as more structurally fragile, whereas platforms that combine real outcomes, resilient economics, and regulatory readiness are emerging as the most compelling partners in the next wave of consumer health investing.
Moderator: Kate Hardey (Bass, Berry & Sims)
Panelists: Amy Shecter (United Aesthetics Alliance), Genevieve Eccleston (Canaccord Genuity), Lavanya Srinivasan (Trive Capital), Pooja Reddy (Greenhill & Co.)
Kayo Healthcare PE Summit Wrap-Up
Across all discussions, a consistent conclusion emerged: Healthcare private equity is moving from growth narratives to proof of execution. As the market matures, investors are increasingly rewarding platforms that demonstrate operational discipline, scalable infrastructure, and durable, diversified growth models, with innovation serving as a tool for value creation, not a substitute for it. The team looks forward to connecting with the Kayo community again in Chicago on November 3, 2026, for the 13th Annual Private Equity Series.